Form 4: Enliven Therapeutics Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares of common stock at an average price of $16.3067 under a pre-arranged 10b5-1 trading plan.

Summary

• On May 19, 2025, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• The shares were sold at prices ranging from $16.00 to $16.90, with a weighted average sale price of $16.3067.
• Following the transaction, Lyssikatos directly owns no shares, but indirectly owns 985,188 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of an insider sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This is a routine disclosure of an insider transaction. The use of a 10b5-1 trading plan suggests the insider is selling shares in a planned and orderly manner to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Form 4, insider trading, share sale, Enliven Therapeutics, ELVN, Lyssikatos, 10b5-1 plan